Survival after reoperation for recurrent glioblastoma multiforme: A prospective study

Furtak, Jacek; Kwiatkowski, A.; Śledzińska, Paulina; Bebyn, Marek; Krajewski, Stanisław; Szylberg, Tadeusz; Birski, Marcin; Druszcz, Adam; Krystkiewicz, Kamil; Gasiński, Piotr; Harat, Marek

doi:10.1016/j.suronc.2022.101771

Cited by 9 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies that investigated potential prognostic factors of OS specifically for patients with recurrent glioblastoma (grade IV glioma) have produced partially conflicting results (2,(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23). In 2012, Bloch et al presented a retrospective study of 107 patients who received resection of recurrent glioblastoma (8).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma

ZEMSKOVA,

YU,

LEPPERT

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma

ZEMSKOVA,

YU,

LEPPERT

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

“…Superselective arterial chemotherapy has attracted increasing attention because of its advantages of relatively low total drug dosage, high local drug concentration, and less systemic reactions and side effects. 23 Therefore, superselective IA cerebral infusion of teniposide for the treatment of glioma patients may be a safely tolerated and feasible strategy.…”

Section: Discussionmentioning

confidence: 99%

Safety and feasibility of intra-arterial delivery of teniposide to high grade gliomas after blood–brain barrier disruption: a case series

Ruan,

Shi,

Luo

et al. 2023

J NeuroIntervent Surg

View full text Add to dashboard Cite

BackgroundThis case series describes the safety and efficacy of superselective intra-arterial (IA) cerebral infusion of teniposide for the treatment of patients with glioma, to provide new ideas and methods for the treatment of high grade gliomas.Methods12 patients with glioma who were previously treated with standard therapy were treated with superselective IA cerebral infusion of teniposide. Patients received at least two cycles of treatment (one cycle: 150 mg/time, used for 1 day, repeated at 28 day intervals) after blood–brain barrier disruption. Patients received individualized treatment on the tumor location. The ophthalmic artery was bypassed during the super-selective arterial infusion.ResultsNo significant differences in biochemical indexes and Karnofsky performance status (KPS) score were observed before and after treatment, and no evident adverse events occurred (P>0.05). In a recent response evaluation (August 2023), two (8%) patients presented with a complete response (16.7%), four had a partial response (33.3%), four had stable disease (33.3%), and two showed progressive disease (16.7%). The overall response rate and disease control rate were 50.0% and 83.3%, respectively. In addition, we described the detailed course of treatment in two patients. Case No 1 (recurrent tumor) and case No 2 (primary tumor) received six and three cycles of teniposide infusion, respectively. After treatment, the tumors of the patients were significantly reduced without evident adverse effects.ConclusionThis small series suggests that superselective IA cerebral infusion of teniposide may be a safe and effective therapy in the multimodal treatment of malignant glioma and warrants further study in larger prospective investigations.

show abstract

“…However, tumor recurrence remains a significant challenge, with some patients experiencing relapse within six months after surgery [ 8 ]. The time interval between initial surgery and recurrence has important prognostic value for patients, and consideration of subsequent treatment options for patients at different risk of recurrence is also highly prioritized [ 9 , 10 ]. For those patients with a high likelihood of recurrence in the short term, the value of surgery, radiotherapy or conservative treatment needs to be individualized and explored.…”

Section: Introductionmentioning

confidence: 99%

Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study

Qiao,

Wang,

Luo

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Glioma recurrence, subsequent to maximal safe resection, remains a pivotal challenge. This study aimed to identify key clinical predictors influencing recurrence and develop predictive models to enhance neurological diagnostics and therapeutic strategies. Methods This longitudinal cohort study with a substantial sample size (n = 2825) included patients with non-recurrent glioma who were pathologically diagnosed and had undergone initial surgical resection between 2010 and 2018. Logistic regression models and stratified Cox proportional hazards models were established with the top 15 clinical variables significantly influencing outcomes screened by the least absolute shrinkage and selection operator (LASSO) method. Preoperative and postoperative models predicting short-term (within 6 months) postoperative recurrence in glioma patients were developed to explore the risk factors associated with short- and long-term recurrence in glioma patients. Results Preoperative and postoperative logistic models predicting short-term recurrence had accuracies of 0.78 and 0.87, respectively. A range of biological and early symptomatic characteristics linked to short- and long-term recurrence have been pinpointed. Age, headache, muscle weakness, tumor location and Karnofsky score represented significant odd ratios (t > 2.65, p < 0.01) in the preoperative model, while age, WHO grade 4 and chemotherapy or radiotherapy treatments (t > 4.12, p < 0.0001) were most significant in the postoperative period. Postoperative predictive models specifically targeting the glioblastoma and IDH wildtype subgroups were also performed, with an AUC of 0.76 and 0.80, respectively. The 50 combinations of distinct risk factors accommodate diverse recurrence risks among glioma patients, and the nomograms visualizes the results for clinical practice. A stratified Cox model identified many prognostic factors for long-term recurrence, thereby facilitating the enhanced formulation of perioperative care plans for patients, and glioblastoma patients displayed a median progression-free survival (PFS) of only 11 months. Conclusion The constructed preoperative and postoperative models reliably predicted short-term postoperative glioma recurrence in a substantial patient cohort. The combinations risk factors and nomograms enhance the operability of personalized therapeutic strategies and care regimens. Particular emphasis should be placed on patients with recurrence within six months post-surgery, and the corresponding treatment strategies require comprehensive clinical investigation.

show abstract

Survival after reoperation for recurrent glioblastoma multiforme: A prospective study

Cited by 9 publications

References 45 publications

Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma

Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma

Safety and feasibility of intra-arterial delivery of teniposide to high grade gliomas after blood–brain barrier disruption: a case series

Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study

Contact Info

Product

Resources

About